---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-046226"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T09:36:24.860423+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.88
calibrated_materiality_score: 0.88
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma to acquire Chimerix for ~$935M ($8.55/sh), adding brain-tumor drug dordaviprone

## Summary
- All-cash tender offer at $8.55/sh; represents ~72% premium over Chimerix's March 4 close.
- Chimerix's dordaviprone (NDA under Priority Review, PDUFA Aug 18, 2025) targets H3 K27M-mutant diffuse glioma.
- If approved, dordaviprone could be first FDA-approved therapy for this rare brain tumor; eligible for Rare Pediatric Disease PRV.
- Jazz expects to fund deal from existing cash; transaction projected to close in Q2 2025.
- Chimerix board unanimously recommends shareholders tender shares; patent protection into 2037 with potential extension.

## SEC filing metadata
- accession: 0001193125-25-046226
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.88
- calibrated_materiality_score: 0.88
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312525046226/0001193125-25-046226-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312525046226/d927269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-046226
- JSON: https://secwatch.observer/filing/0001193125-25-046226.json
- Plain text: https://secwatch.observer/filing/0001193125-25-046226.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.